Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Inclusion Criteria:

histologically or cytologically documented relapsed and/or refractory hematologic malignancy
Karnofsky Performance Status (KPS) of >70%.
Must be ≥18 years of age.
Expected survival >1 month.
Women of child-bearing potential must use accepted contraceptive methods
No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 3 weeks prior to treatment with CPI-613.

Exclusion Criteria:

Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity.
Patients with active central nervous system (CNS) or epidural tumor.
Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease).
Pregnant women, or women of child-bearing potential not using reliable means of contraception.
Lactating females because the potential of excretion of CPI-613 into breast milk.
Life expectancy less than 1 month.
Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.